Overall, these results point out a relevant conclusion: both pro-BDNF/p75 signalling and the ratio pro-BDNF/BDNF measured in the CSF could be considered potential diagnostic biomarkers to develop new therapeutic approaches for AD. This evidence concerns the gene BDNF and Alzheimer disease.